CytoMed Therapeutics Ltd

GDTC

Explore Our Financial Data > Companies > CytoMed Therapeutics Ltd
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
GDTC
CIK0001873093
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, U0, 149544
Website w2.cytomed.sg
Phone603824911
CEOChee Kong Choo
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$268,662.00
Pre-Tax Income$-1.85 million
Net Income$-1.85 million
Net Income to Common$-1.85 million
EPSN/A
View All
Balance Sheet
Cash$3.64 million
Assets$7.37 million
Liabilities$749,495.00
Common Equity$6.56 million
Liabilities & Equity$7.37 million
View All
Cash Flow Statement
Net Income$-1.85 million
Cash From Operating Activities$-76,060.36
Cash From Investing Activities$-1.02 million
Cash From Financing Activities$0.00
Change in Cash$-1.10 million
View All
Calculations
NOPAT$-1.29 million
EBITDA$-1.76 million
Price to EarningsN/A
Price to Book$3.91
ROE-24.20%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CytoMed Therapeutics ( NASDAQ:GDTC ) Full Year 2024 Results Key Financial Results Net loss: S$2.52m (loss narrowed by...

Article Link

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024

Article Link

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board of Directors (the “Board”) as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year o

Article Link

Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

As the U.S. stock market reacts to tariff news and a wave of earnings reports, major indices like the S&P 500 and Nasdaq Composite are seeing upward movement. For investors considering smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area with potential value. These stocks can offer unique growth opportunities, especially when backed by strong financials, as we explore several promising candidates in this article.

Article Link

CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India

The latest announcement is out from CytoMed Therapeutics Limited ( (GDTC) ). CytoMed Therapeutics has entered a collaboration with SunAct Cancer Institute in India to advance the use of its allogeneic gamma delta T cells in a Phase 2 clinical trial aimed at treating solid cancers. This partnership seeks to explore the therapy’s safety and efficacy, potentially providing an affordable treatment option for cancer patients in India, while contributing to global cancer research data. More about Cyto

Article Link